A Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Lenvatinib (E7080/MK-7902) plus Pembrolizumab (MK-3475) plus Chemotherapy Compared with Standard of Care Therapy as First-line Intervention in Participants with Advanced/Metastatic Gastroesophageal Adenocarcinoma (LEAP-015)
Active, not recruitingCTIS2023-504834-23-00
Merck Sharp & Dohme LLCAdvanced/Metastatic Gastroesophageal Adenocarcinoma
Start: 2021-02-24Target: 231Updated: 2025-12-17